secwatch.observer — SEC 8-K summary
======================================

Issuer:     Parabilis Medicines, Inc. (PBLS)
CIK:        0001657677
Form:       8-K
Filed at:   2026-09-02T20:05:15+00:00
Accession:  0001193125-26-380171
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Parabilis Medicines CMO Fawzi Benzaghou to depart effective Sept 30, 2026
-------------------------------------------------------------------------

- Chief Medical Officer Fawzi Benzaghou, M.D. and company mutually agreed to his transition, effective September 30, 2026.
- Dr. Benzaghou will receive severance benefits pursuant to his employment agreement.
- No replacement CMO has been named in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657677/000119312526380171/0001193125-26-380171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657677/000119312526380171/ck0001657677-20260828.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-380171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer